South Korea will allocate 90 billion won by next year for electrofuel research and development projects, in pursuance of eliminating its carbon emissions by 2050.
The Ministry of Trade, Industry and Energy said that along with promoting the sales of electric cars and hydrogen fuel cell vehicles, the country needs to diversify its technology portfolio to beef up its automobile industry's competitiveness.
Electrofuel is an environment-friendly sourced alternative to fossil fuels used in traditional automobiles. It is produced by synthesizing gases with hydrogen.
South Korea plans to have eco-friendly cars, including hydrogen fuel cell cars, comprise 30 percent of its total registered automobiles by 2030 from the current 3 percent.


Australian Household Spending Dips in December as RBA Tightens Policy
China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Russian Stocks End Mixed as MOEX Index Closes Flat Amid Commodity Strength
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Dow Hits 50,000 as U.S. Stocks Stage Strong Rebound Amid AI Volatility
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal
Trump’s Inflation Claims Clash With Voters’ Cost-of-Living Reality
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record
Nikkei 225 Hits Record High Above 56,000 After Japan Election Boosts Market Confidence
U.S. Stock Futures Slide as Tech Rout Deepens on Amazon Capex Shock
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 



